Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

Combination docetaxel + vandetanib did not prolong PFS relative to docetaxel alone in OC patients. No unexpected safety issues were identified.